valproic acid has been researched along with Anxiety in 76 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-six patients with anxious (n = 21) and non-anxious (n = 15) treatment-resistant bipolar depression (types I and II; concurrently treated with either lithium or valproate) received a single infusion of ketamine (0." | 9.20 | A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. ( Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Zarate, CA, 2015) |
| " VPA-exposed male pups were administered with two doses of ibudilast (5 and10 mg/kg) and all the groups were evaluated for behavioral parameters like social interaction, spatial memory/learning, anxiety, locomotor activity, and nociceptive threshold." | 8.31 | Phosphodiesterase inhibitor, ibudilast alleviates core behavioral and biochemical deficits in the prenatal valproic acid exposure model of autism spectrum disorder. ( Gautam, V; Kumar, A; Rawat, K; Saha, L; Sandhu, A; Sharma, A, 2023) |
| " Therefore, in this study, we focused on the rapid and persistent neuroprotective function of DLX following valproic acid (VPA)-triggered hyperactivity, anxiety-like behavior and social deficits in zebrafish." | 8.12 | Duloxetine ameliorates valproic acid-induced hyperactivity, anxiety-like behavior, and social interaction deficits in zebrafish. ( Chen, H; Joseph, TP; Lin, SL; Sai, LY; Schachner, M; Zhou, F, 2022) |
| " The anxiety induced by pilocarpine was also significantly (P < 0." | 8.12 | Anticonvulsant effects of Cymbopogon giganteus extracts with possible effects on fully kindled seizures and anxiety in experimental rodent model of mesio-temporal epilepsy induced by pilocarpine. ( Bum, EN; Kouemou Emegam, N; Neteydji, S; Pale, S; Taiwe, GS, 2022) |
| " Here in this study, we found significant demyelination in the hippocampus of the mouse cuprizone model, which is accompanied by reduced cholesterol biosynthesis and increased anxiety-like behavior." | 8.02 | Valproic acid suppresses cuprizone-induced hippocampal demyelination and anxiety-like behavior by promoting cholesterol biosynthesis. ( Gan, G; He, Y; Hu, Y; Liu, X; Yang, J; Yao, Y; Zhang, A; Zhang, C; Zhu, X, 2021) |
| "The cilostazol regimen, attenuated prenatal VPA exposure associated hyperlocomotion, social interaction deficits, repetitive behavior, and anxiety." | 8.02 | Cilostazol attenuated prenatal valproic acid-induced behavioural and biochemical deficits in a rat model of autism spectrum disorder. ( Kulkarni, GT; Luhach, K; Sharma, B; Singh, VP, 2021) |
| "This study was performed to evaluate the effects of prenatal exposure to pregabalin (PGB) on behavioral changes of rat offspring in an animal model of valproic acid (VPA)-induced autism-like symptoms." | 7.96 | Prenatal pregabalin is associated with sex-dependent alterations in some behavioral parameters in valproic acid-induced autism in rat offspring. ( Bashiri, H; Moslemizadeh, A; Sepehri, G; Shamsi Meymandi, M; Vakili Shahrbabaki, S, 2020) |
| " Valproic acid (VPA) is an anticonvulsant drug in both human and rodents with teratogenic effects during pregnancy." | 7.91 | Benefits of Fenofibrate in prenatal valproic acid-induced autism spectrum disorder related phenotype in rats. ( Mirza, R; Sharma, B, 2019) |
| "Irritability has been described as a frequent adverse event in patients affected by epilepsy and treated with perampanel (PER), levetiracetam (LEV), and less frequently with valproic acid (VPA)." | 7.91 | Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add-on therapy compared to levetiracetam and valproic acid. ( Assogna, M; Canevini, MP; Izzi, F; Liguori, C; Mercuri, NB; Placidi, F; Turner, K, 2019) |
| ") on sociability, social novelty, anxiety, and aggressive/repetitive behavior in male Tuck-Ordinary (TO) mice with ASD-like behaviors induced by prenatal exposure to valproic acid (VPA, 500 mg/kg, i." | 7.88 | The histamine H3R antagonist DL77 attenuates autistic behaviors in a prenatal valproic acid-induced mouse model of autism. ( Al-Houqani, M; Azimullah, S; Eissa, N; Jalal, FY; Jayaprakash, P; Kieć-Kononowicz, K; Ojha, SK; Sadek, B; Łażewska, D, 2018) |
| "Post natal exposure to VPA (valproic acid) in mice induces behavioral deficits, abnormal sensitivity to sensory stimuli and self-injurious behavior, observed in autism." | 7.80 | Ameliorating effect of piperine on behavioral abnormalities and oxidative markers in sodium valproate induced autism in BALB/C mice. ( Kameshwari, JS; Pragnya, B; Veeresh, B, 2014) |
| "An open pilot study to evaluate the effect of pregabalin (PGB) as add-on therapy on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy (BTRE)." | 7.78 | Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. ( Carapella, CM; Dinapoli, L; Fabi, A; Maschio, M; Pace, A; Pompili, A; Sperati, F; Vidiri, A, 2012) |
| "This retrospective study examined adjunct divalproex (N = 15) or lithium (N = 9) in treatment-resistant schizophrenia patients added to clozapine and compared to clozapine monotherapy (N = 25)." | 7.73 | Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. ( Conley, RR; Feldman, S; Kelly, DL; McMahon, RP; Richardson, CM; Yu, Y, 2006) |
| "Valproic acid (VPA) is a drug used for the treatment of epilepsy, seizures, migraines, and bipolar disorders." | 5.72 | Valproic Acid-Induced Anxiety and Depression Behaviors are Ameliorated in p39 Cdk5 Activator-Deficient Mice. ( Ando, K; Hisanaga, SI; Kawakami, A; Ohshima, T; Takahashi, M; Takasugi, T; Wei, R, 2022) |
| "The social motivational theory of autism spectrum disorder (ASD) focuses on social anhedonia as key causal feature of the impaired peer relationships that characterize ASD patients." | 5.56 | Targeting PPARα in the rat valproic acid model of autism: focus on social motivational impairment and sex-related differences. ( Braccagni, G; De Montis, MG; Gambarana, C; Guzzi, F; Parenti, M; Scheggi, S, 2020) |
| "Valproic acid (600 mg/kg) was administered intraperitoneally to the pregnant mice on gestational day 12." | 5.42 | Astaxanthin improves behavioral disorder and oxidative stress in prenatal valproic acid-induced mice model of autism. ( Al-Amin, MM; Khan, FR; Mahmud Reza, H; Rahman, MM; Zaman, F, 2015) |
| "Thirty-six patients with anxious (n = 21) and non-anxious (n = 15) treatment-resistant bipolar depression (types I and II; concurrently treated with either lithium or valproate) received a single infusion of ketamine (0." | 5.20 | A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. ( Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Zarate, CA, 2015) |
| "Pregabalin effectively reduced the severity of PTSD symptoms but it was not effective in improving the severity of depression, anxiety, and quality of life." | 5.19 | Effect of pregabalin augmentation in treatment of patients with combat-related chronic posttraumatic stress disorder: a randomized controlled trial. ( Baniasadi, M; Fayyazi Bordbar, MR; Hosseini, G; Mostafavi Toroghi, H; Rezaei Ardani, A, 2014) |
| "The prenatal valproic acid (VPA) model was used to induce autism-like behaviors in offspring rats." | 4.31 | Inhalation of Cananga odorata essential oil relieves anxiety behaviors in autism-like rats via regulation of serotonin and dopamine metabolism. ( Wang, ST; Yao, L; Zhang, N, 2023) |
| " VPA-exposed male pups were administered with two doses of ibudilast (5 and10 mg/kg) and all the groups were evaluated for behavioral parameters like social interaction, spatial memory/learning, anxiety, locomotor activity, and nociceptive threshold." | 4.31 | Phosphodiesterase inhibitor, ibudilast alleviates core behavioral and biochemical deficits in the prenatal valproic acid exposure model of autism spectrum disorder. ( Gautam, V; Kumar, A; Rawat, K; Saha, L; Sandhu, A; Sharma, A, 2023) |
| " Therefore, in this study, we focused on the rapid and persistent neuroprotective function of DLX following valproic acid (VPA)-triggered hyperactivity, anxiety-like behavior and social deficits in zebrafish." | 4.12 | Duloxetine ameliorates valproic acid-induced hyperactivity, anxiety-like behavior, and social interaction deficits in zebrafish. ( Chen, H; Joseph, TP; Lin, SL; Sai, LY; Schachner, M; Zhou, F, 2022) |
| " The anxiety induced by pilocarpine was also significantly (P < 0." | 4.12 | Anticonvulsant effects of Cymbopogon giganteus extracts with possible effects on fully kindled seizures and anxiety in experimental rodent model of mesio-temporal epilepsy induced by pilocarpine. ( Bum, EN; Kouemou Emegam, N; Neteydji, S; Pale, S; Taiwe, GS, 2022) |
| "The cilostazol regimen, attenuated prenatal VPA exposure associated hyperlocomotion, social interaction deficits, repetitive behavior, and anxiety." | 4.02 | Cilostazol attenuated prenatal valproic acid-induced behavioural and biochemical deficits in a rat model of autism spectrum disorder. ( Kulkarni, GT; Luhach, K; Sharma, B; Singh, VP, 2021) |
| " Here in this study, we found significant demyelination in the hippocampus of the mouse cuprizone model, which is accompanied by reduced cholesterol biosynthesis and increased anxiety-like behavior." | 4.02 | Valproic acid suppresses cuprizone-induced hippocampal demyelination and anxiety-like behavior by promoting cholesterol biosynthesis. ( Gan, G; He, Y; Hu, Y; Liu, X; Yang, J; Yao, Y; Zhang, A; Zhang, C; Zhu, X, 2021) |
| "This study was performed to evaluate the effects of prenatal exposure to pregabalin (PGB) on behavioral changes of rat offspring in an animal model of valproic acid (VPA)-induced autism-like symptoms." | 3.96 | Prenatal pregabalin is associated with sex-dependent alterations in some behavioral parameters in valproic acid-induced autism in rat offspring. ( Bashiri, H; Moslemizadeh, A; Sepehri, G; Shamsi Meymandi, M; Vakili Shahrbabaki, S, 2020) |
| " Valproic acid (VPA) is an anticonvulsant drug in both human and rodents with teratogenic effects during pregnancy." | 3.91 | Benefits of Fenofibrate in prenatal valproic acid-induced autism spectrum disorder related phenotype in rats. ( Mirza, R; Sharma, B, 2019) |
| "Irritability has been described as a frequent adverse event in patients affected by epilepsy and treated with perampanel (PER), levetiracetam (LEV), and less frequently with valproic acid (VPA)." | 3.91 | Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add-on therapy compared to levetiracetam and valproic acid. ( Assogna, M; Canevini, MP; Izzi, F; Liguori, C; Mercuri, NB; Placidi, F; Turner, K, 2019) |
| ") on sociability, social novelty, anxiety, and aggressive/repetitive behavior in male Tuck-Ordinary (TO) mice with ASD-like behaviors induced by prenatal exposure to valproic acid (VPA, 500 mg/kg, i." | 3.88 | The histamine H3R antagonist DL77 attenuates autistic behaviors in a prenatal valproic acid-induced mouse model of autism. ( Al-Houqani, M; Azimullah, S; Eissa, N; Jalal, FY; Jayaprakash, P; Kieć-Kononowicz, K; Ojha, SK; Sadek, B; Łażewska, D, 2018) |
| "Prenatal exposure to the antiepileptic and mood stabilizer valproic acid (VPA) is an environmental risk factor for autism spectrum disorders (ASD), although recent epidemiological studies show that the public awareness of this association is still limited." | 3.88 | Impaired repair of DNA damage is associated with autistic-like traits in rats prenatally exposed to valproic acid. ( Ascenzi, P; Campolongo, P; di Masi, A; Leboffe, L; Manduca, A; Melancia, F; Palmery, M; Schiavi, S; Servadio, M; Trezza, V, 2018) |
| " Its etiology is still unknown, but different environmental factors during pregnancy, such as exposure to valproic acid (VPA), are associated with high incidence of ASD in children." | 3.85 | The effect of ketogenic diet in an animal model of autism induced by prenatal exposure to valproic acid. ( Baronio, D; Castro, K; Gottfried, C; Perry, IS; Riesgo, RDS, 2017) |
| "A single treatment of valproate and olanzapine did not ameliorate the hyperactivity or abnormal anxiety level of DGKβ KO mice." | 3.81 | The effects of valproate and olanzapine on the abnormal behavior of diacylglycerol kinase β knockout mice. ( Hara, H; Ishisaka, M; Mizoguchi, T; Shimazawa, M; Tsujii, S; Tsuruma, K, 2015) |
| "Post natal exposure to VPA (valproic acid) in mice induces behavioral deficits, abnormal sensitivity to sensory stimuli and self-injurious behavior, observed in autism." | 3.80 | Ameliorating effect of piperine on behavioral abnormalities and oxidative markers in sodium valproate induced autism in BALB/C mice. ( Kameshwari, JS; Pragnya, B; Veeresh, B, 2014) |
| "An open pilot study to evaluate the effect of pregabalin (PGB) as add-on therapy on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy (BTRE)." | 3.78 | Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. ( Carapella, CM; Dinapoli, L; Fabi, A; Maschio, M; Pace, A; Pompili, A; Sperati, F; Vidiri, A, 2012) |
| "This retrospective study examined adjunct divalproex (N = 15) or lithium (N = 9) in treatment-resistant schizophrenia patients added to clozapine and compared to clozapine monotherapy (N = 25)." | 3.73 | Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. ( Conley, RR; Feldman, S; Kelly, DL; McMahon, RP; Richardson, CM; Yu, Y, 2006) |
| " In particular, considerable inconsistency has been noted both for the effects of GABAergic manipulations in animal models of anxiety and the ability of GABA(A) receptor antagonists to block the anxiolytic effects of diazepam (DZ) and chlordiazepoxide." | 3.71 | Anxiolytic effects of valproate and diazepam in mice are differentially sensitive to picrotoxin antagonism. ( Dalvi, A; Rodgers, RJ, 2001) |
| "An experimental and clinico-pharmacological study of sodium valproate, a GABA-ergic drug, was conducted to elucidate the role of gamma-aminobutyric acid in the mechanisms responsible for affective disturbances, in particular for anxiety." | 3.67 | [Anxiolytic action of sodium valproate (possible role of gamma-aminobutyric acid in affective disorders)]. ( Aleksandrovskiĭ, IuA; Kharlamov, AN; Neznamov, GG; Poiurovskiĭ, MV; Raevskiĭ, KS, 1985) |
| "The progression in severity of withdrawal symptoms (increase in CIWA-Ar above baseline) was also significantly greater in the placebo group (p < 0." | 2.70 | Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. ( Baer, JS; Malte, CA; Reoux, JP; Saxon, AJ; Sloan, KL, 2001) |
| "The social motivational theory of autism spectrum disorder (ASD) focuses on social anhedonia as key causal feature of the impaired peer relationships that characterize ASD patients." | 1.56 | Targeting PPARα in the rat valproic acid model of autism: focus on social motivational impairment and sex-related differences. ( Braccagni, G; De Montis, MG; Gambarana, C; Guzzi, F; Parenti, M; Scheggi, S, 2020) |
| " Treatment with VPA induced Ncs-1 gene expression in cell line while chronic administration of this drug to mice increased both Ncs-1 protein and mRNA levels in the mouse frontal cortex." | 1.56 | Contribution of neuronal calcium sensor 1 (Ncs-1) to anxiolytic-like and social behavior mediated by valproate and Gsk3 inhibition. ( Beaulieu, JM; Collodetti, M; Del'Guidice, T; Khlghatyan, J; Magno, LAV; Nicolau, ES; Romano-Silva, MA; Tenza-Ferrer, H, 2020) |
| "Treatment with pioglitazone significantly attenuated the prenatal VPA-induced social impairment, repetitive behavior, hyperactivity, anxiety and low exploratory activity." | 1.51 | Beneficial effects of pioglitazone, a selective peroxisome proliferator-activated receptor-γ agonist in prenatal valproic acid-induced behavioral and biochemical autistic like features in Wistar rats. ( Mirza, R; Sharma, B, 2019) |
| "All patients ≥16years of age with epilepsy for ≥12months were routinely asked to complete the Liverpool Adverse Event Profile (LAEP) just before their appointment." | 1.43 | Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study. ( Fidzinski, P; Gaus, V; Holtkamp, M; Kowski, AB; Losch, F; Weissinger, F, 2016) |
| "Valproic acid (600 mg/kg) was administered intraperitoneally to the pregnant mice on gestational day 12." | 1.42 | Astaxanthin improves behavioral disorder and oxidative stress in prenatal valproic acid-induced mice model of autism. ( Al-Amin, MM; Khan, FR; Mahmud Reza, H; Rahman, MM; Zaman, F, 2015) |
| "Multiple generalized seizures occurred in all homozygous mice around three weeks after birth." | 1.42 | Epileptogenesis and epileptic maturation in phosphorylation site-specific SNAP-25 mutant mice. ( Kataoka, M; Miyaoka, H; Otsuka, S; Saito, M; Suzuki, E; Takahashi, M; Watanabe, S; Yamamori, S, 2015) |
| "He had a subsequent syncopal episode and despite accidental destruction of his patient activator, vital ECG data from the event were transmitted wirelessly, enabling a cardiac arrhythmia to be excluded." | 1.36 | All is not lost: utilizing continuous remote ILR monitoring to diagnose syncope. ( Hong, PS; Sulke, N; Veasey, RA, 2010) |
| "The families of 42 children with febrile seizures were recruited after pediatric or neuropediatric consultation." | 1.31 | Treatment of febrile seizures: the influence of treatment efficacy and side-effect profile on value to parents. ( Camfield, CS; Camfield, PR; Dooley, JM; Gordon, KE; MacSween, J, 2001) |
| " In this pilot study 13 adult male alcoholics received one month of oral, low dose sodium valproate (15 mg/kg/d) followed by one month of placebo followed by one month of sodium valproate at the standard anticonvulsant dosage (45 mg/kg/d)." | 1.29 | The use of sodium valproate in the treatment of alcoholism. ( Borrett, G; Duerksen, DR; German, GB; Hoeschen, L; Minuk, GY; Rockman, GE, 1995) |
| ") was antagonized by the chronic administration of lorazepam as well as sodium valproate, a GABA agonist." | 1.28 | The anxiogenic-like effects of pentylenetetrazole in mice treated chronically with carbamazepine or valproate. ( de Angelis, L, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.63) | 18.7374 |
| 1990's | 6 (7.89) | 18.2507 |
| 2000's | 15 (19.74) | 29.6817 |
| 2010's | 35 (46.05) | 24.3611 |
| 2020's | 18 (23.68) | 2.80 |
| Authors | Studies |
|---|---|
| Tomczuk, BE | 1 |
| Taylor, CR | 1 |
| Moses, LM | 1 |
| Sutherland, DB | 1 |
| Lo, YS | 1 |
| Johnson, DN | 1 |
| Kinnier, WB | 1 |
| Kilpatrick, BF | 1 |
| Luhach, K | 1 |
| Kulkarni, GT | 1 |
| Singh, VP | 1 |
| Sharma, B | 3 |
| Zhu, X | 1 |
| Yao, Y | 1 |
| Hu, Y | 1 |
| Yang, J | 1 |
| Zhang, C | 2 |
| He, Y | 1 |
| Zhang, A | 1 |
| Liu, X | 1 |
| Gan, G | 1 |
| Yatham, LN | 1 |
| Chakrabarty, T | 1 |
| Bond, DJ | 1 |
| Schaffer, A | 1 |
| Beaulieu, S | 1 |
| Parikh, SV | 1 |
| McIntyre, RS | 1 |
| Milev, RV | 1 |
| Alda, M | 1 |
| Vazquez, G | 1 |
| Ravindran, AV | 1 |
| Frey, BN | 1 |
| Sharma, V | 1 |
| Goldstein, BI | 1 |
| Rej, S | 1 |
| O'Donovan, C | 1 |
| Tourjman, V | 1 |
| Kozicky, JM | 1 |
| Kauer-Sant'Anna, M | 1 |
| Malhi, G | 1 |
| Suppes, T | 1 |
| Vieta, E | 1 |
| Kapczinski, F | 1 |
| Kanba, S | 1 |
| Lam, RW | 1 |
| Kennedy, SH | 1 |
| Calabrese, J | 1 |
| Berk, M | 1 |
| Post, R | 1 |
| Joseph, TP | 1 |
| Zhou, F | 1 |
| Sai, LY | 1 |
| Chen, H | 1 |
| Lin, SL | 1 |
| Schachner, M | 1 |
| Pale, S | 1 |
| Neteydji, S | 1 |
| Taiwe, GS | 1 |
| Kouemou Emegam, N | 1 |
| Bum, EN | 1 |
| Nouri, E | 1 |
| Karimi, SA | 1 |
| Raoufi, S | 1 |
| Zarei, M | 1 |
| Takahashi, M | 2 |
| Takasugi, T | 1 |
| Kawakami, A | 1 |
| Wei, R | 1 |
| Ando, K | 1 |
| Ohshima, T | 1 |
| Hisanaga, SI | 1 |
| Zhang, N | 1 |
| Wang, ST | 1 |
| Yao, L | 1 |
| Shahrbabaki, SSV | 1 |
| Moslemizadeh, A | 2 |
| Amiresmaili, S | 1 |
| Tezerji, SS | 1 |
| Juybari, KB | 1 |
| Sepehri, G | 2 |
| Shamsi Meymandi, M | 2 |
| Bashiri, H | 2 |
| Sandhu, A | 1 |
| Rawat, K | 1 |
| Gautam, V | 1 |
| Sharma, A | 2 |
| Kumar, A | 1 |
| Saha, L | 1 |
| Wang, J | 1 |
| Feng, S | 1 |
| Li, M | 1 |
| Liu, Y | 1 |
| Yan, J | 1 |
| Tang, Y | 1 |
| Du, D | 1 |
| Chen, F | 1 |
| Magno, LAV | 1 |
| Tenza-Ferrer, H | 1 |
| Collodetti, M | 1 |
| Nicolau, ES | 1 |
| Khlghatyan, J | 1 |
| Del'Guidice, T | 1 |
| Romano-Silva, MA | 1 |
| Beaulieu, JM | 1 |
| Ozkul, Y | 1 |
| Taheri, S | 1 |
| Bayram, KK | 1 |
| Sener, EF | 1 |
| Mehmetbeyoglu, E | 1 |
| Öztop, DB | 1 |
| Aybuga, F | 1 |
| Tufan, E | 1 |
| Bayram, A | 1 |
| Dolu, N | 1 |
| Zararsiz, G | 1 |
| Kianmehr, L | 1 |
| Beyaz, F | 1 |
| Doganyigit, Z | 1 |
| Cuzin, F | 1 |
| Rassoulzadegan, M | 1 |
| Vakili Shahrbabaki, S | 1 |
| Scheggi, S | 1 |
| Guzzi, F | 1 |
| Braccagni, G | 1 |
| De Montis, MG | 1 |
| Parenti, M | 1 |
| Gambarana, C | 1 |
| Messina, A | 1 |
| Boiti, A | 1 |
| Sovrano, VA | 1 |
| Sgadò, P | 1 |
| Alò, R | 1 |
| Olivito, I | 1 |
| Fazzari, G | 1 |
| Zizza, M | 1 |
| Di Vito, A | 1 |
| Avolio, E | 1 |
| Mandalà, M | 1 |
| Bruno, R | 1 |
| Barni, T | 1 |
| Canonaco, M | 1 |
| Facciolo, RM | 1 |
| Thornton, AM | 1 |
| Humphrey, RM | 1 |
| Kerr, DM | 1 |
| Finn, DP | 1 |
| Roche, M | 1 |
| Lindley, RI | 1 |
| Bath, KG | 1 |
| Pimentel, T | 1 |
| Jamal, I | 1 |
| Kumar, V | 1 |
| Vatsa, N | 1 |
| Shekhar, S | 1 |
| Singh, BK | 1 |
| Jana, NR | 1 |
| Servadio, M | 1 |
| Manduca, A | 1 |
| Melancia, F | 1 |
| Leboffe, L | 1 |
| Schiavi, S | 1 |
| Campolongo, P | 1 |
| Palmery, M | 1 |
| Ascenzi, P | 1 |
| di Masi, A | 1 |
| Trezza, V | 1 |
| Maddaloni, G | 1 |
| Migliarini, S | 1 |
| Napolitano, F | 1 |
| Giorgi, A | 1 |
| Nazzi, S | 1 |
| Biasci, D | 1 |
| De Felice, A | 1 |
| Gritti, M | 1 |
| Cavaccini, A | 1 |
| Galbusera, A | 1 |
| Franceschi, S | 1 |
| Lessi, F | 1 |
| Ferla, M | 1 |
| Aretini, P | 1 |
| Mazzanti, CM | 1 |
| Tonini, R | 1 |
| Gozzi, A | 1 |
| Usiello, A | 1 |
| Pasqualetti, M | 1 |
| Bach, DR | 1 |
| Korn, CW | 1 |
| Vunder, J | 1 |
| Bantel, A | 1 |
| Silva, EF | 1 |
| Silva, AI | 1 |
| Asth, L | 1 |
| Souza, LS | 1 |
| Zaveri, NT | 1 |
| Guerrini, R | 1 |
| Calo', G | 1 |
| Ruzza, C | 1 |
| Gavioli, EC | 1 |
| Eissa, N | 1 |
| Jayaprakash, P | 1 |
| Azimullah, S | 1 |
| Ojha, SK | 1 |
| Al-Houqani, M | 1 |
| Jalal, FY | 1 |
| Łażewska, D | 1 |
| Kieć-Kononowicz, K | 1 |
| Sadek, B | 1 |
| Liguori, C | 1 |
| Turner, K | 1 |
| Izzi, F | 1 |
| Assogna, M | 1 |
| Canevini, MP | 1 |
| Mercuri, NB | 1 |
| Placidi, F | 1 |
| Mirza, R | 2 |
| Sailer, L | 1 |
| Duclot, F | 1 |
| Wang, Z | 1 |
| Kabbaj, M | 1 |
| Oguchi-Katayama, A | 1 |
| Monma, A | 1 |
| Sekino, Y | 1 |
| Moriguchi, T | 1 |
| Sato, K | 1 |
| Liu, D | 1 |
| Qiu, HM | 1 |
| Fei, HZ | 1 |
| Hu, XY | 1 |
| Xia, HJ | 1 |
| Wang, LJ | 1 |
| Qin, LJ | 1 |
| Jiang, XH | 1 |
| Zhou, QX | 1 |
| Wilson, CB | 1 |
| McLaughlin, LD | 1 |
| Ebenezer, PJ | 1 |
| Nair, AR | 1 |
| Francis, J | 1 |
| Burenkova, OV | 1 |
| Aleksandrova, EA | 1 |
| Zaraiskaya, IY | 1 |
| Pragnya, B | 1 |
| Kameshwari, JS | 1 |
| Veeresh, B | 1 |
| Ionescu, DF | 1 |
| Luckenbaugh, DA | 1 |
| Niciu, MJ | 1 |
| Richards, EM | 1 |
| Zarate, CA | 1 |
| Baniasadi, M | 1 |
| Hosseini, G | 1 |
| Fayyazi Bordbar, MR | 1 |
| Rezaei Ardani, A | 1 |
| Mostafavi Toroghi, H | 1 |
| Ishisaka, M | 1 |
| Tsujii, S | 1 |
| Mizoguchi, T | 1 |
| Tsuruma, K | 1 |
| Shimazawa, M | 1 |
| Hara, H | 1 |
| Al-Amin, MM | 1 |
| Rahman, MM | 1 |
| Khan, FR | 1 |
| Zaman, F | 1 |
| Mahmud Reza, H | 1 |
| Barker-Haliski, ML | 1 |
| Dahle, EJ | 1 |
| Heck, TD | 1 |
| Pruess, TH | 1 |
| Vanegas, F | 1 |
| Wilcox, KS | 1 |
| White, HS | 1 |
| Lazic, SE | 1 |
| Watanabe, S | 1 |
| Yamamori, S | 1 |
| Otsuka, S | 1 |
| Saito, M | 1 |
| Suzuki, E | 1 |
| Kataoka, M | 1 |
| Miyaoka, H | 1 |
| Wang, CY | 1 |
| Cheng, CW | 1 |
| Wang, WH | 1 |
| Chen, PS | 1 |
| Tzeng, SF | 1 |
| Kowski, AB | 1 |
| Weissinger, F | 1 |
| Gaus, V | 1 |
| Fidzinski, P | 1 |
| Losch, F | 1 |
| Holtkamp, M | 1 |
| Castro, K | 1 |
| Baronio, D | 1 |
| Perry, IS | 1 |
| Riesgo, RDS | 1 |
| Gottfried, C | 1 |
| Yang, Y | 1 |
| Cheng, Z | 1 |
| Tang, H | 1 |
| Jiao, H | 1 |
| Sun, X | 1 |
| Cui, Q | 1 |
| Luo, F | 1 |
| Pan, H | 1 |
| Ma, C | 1 |
| Li, B | 1 |
| Olexová, L | 1 |
| Štefánik, P | 1 |
| Kršková, L | 1 |
| Ha, S | 1 |
| Park, H | 1 |
| Mahmood, U | 1 |
| Ra, JC | 1 |
| Suh, YH | 1 |
| Chang, KA | 1 |
| Kelly, MP | 1 |
| Logue, SF | 1 |
| Dwyer, JM | 1 |
| Beyer, CE | 1 |
| Majchrowski, H | 1 |
| Cai, Z | 1 |
| Liu, Z | 1 |
| Adedoyin, A | 1 |
| Rosenzweig-Lipson, S | 1 |
| Comery, TA | 1 |
| España, J | 1 |
| Giménez-Llort, L | 1 |
| Valero, J | 1 |
| Miñano, A | 1 |
| Rábano, A | 1 |
| Rodriguez-Alvarez, J | 1 |
| LaFerla, FM | 1 |
| Saura, CA | 1 |
| Barbier, E | 1 |
| Wang, JB | 1 |
| Hong, PS | 1 |
| Veasey, RA | 1 |
| Sulke, N | 1 |
| Bogdanov, VB | 1 |
| Bogdanova, OV | 1 |
| Koulchitsky, SV | 1 |
| Chauvel, V | 1 |
| Multon, S | 1 |
| Makarchuk, MY | 1 |
| Brennan, KC | 1 |
| Renshaw, PF | 1 |
| Schoenen, J | 1 |
| Yang, EJ | 1 |
| Lin, EW | 1 |
| Hensch, TK | 1 |
| Maschio, M | 1 |
| Dinapoli, L | 1 |
| Sperati, F | 1 |
| Pace, A | 1 |
| Fabi, A | 1 |
| Vidiri, A | 1 |
| Pompili, A | 1 |
| Carapella, CM | 1 |
| Lang, AP | 1 |
| de Angelis, L | 3 |
| Vance, H | 1 |
| Kauffman, C | 1 |
| Miller, B | 1 |
| Mansour, T | 1 |
| Davis, LL | 1 |
| Bartolucci, A | 1 |
| Petty, F | 1 |
| Junig, JT | 1 |
| Lehrmann, JA | 1 |
| Schneider, T | 2 |
| Turczak, J | 1 |
| Przewłocki, R | 2 |
| Debattista, C | 1 |
| Solomon, A | 1 |
| Arnow, B | 1 |
| Kendrick, E | 1 |
| Tilston, J | 1 |
| Schatzberg, AF | 1 |
| Kelly, DL | 1 |
| Conley, RR | 1 |
| Feldman, S | 1 |
| Yu, Y | 1 |
| McMahon, RP | 1 |
| Richardson, CM | 1 |
| Dombrowski, PA | 1 |
| Fernandes, LH | 1 |
| Andreatini, R | 1 |
| Siniscalchi, A | 1 |
| Gallelli, L | 1 |
| De Fazio, S | 1 |
| De Sarro, G | 1 |
| Ziòłkowska, B | 1 |
| Gieryk, A | 1 |
| Tyminska, A | 1 |
| Minuk, GY | 1 |
| Rockman, GE | 1 |
| German, GB | 1 |
| Duerksen, DR | 1 |
| Borrett, G | 1 |
| Hoeschen, L | 1 |
| Dalvi, A | 1 |
| Rodgers, RJ | 1 |
| Reoux, JP | 1 |
| Saxon, AJ | 1 |
| Malte, CA | 1 |
| Baer, JS | 1 |
| Sloan, KL | 1 |
| Gordon, KE | 1 |
| Dooley, JM | 1 |
| Camfield, PR | 1 |
| Camfield, CS | 1 |
| MacSween, J | 1 |
| Altshuler, LL | 1 |
| Devinsky, O | 1 |
| Post, RM | 1 |
| Theodore, W | 1 |
| Vinar, O | 1 |
| Dvorák, A | 1 |
| Vinarová, E | 1 |
| Fácková, M | 1 |
| Pavlícek, N | 1 |
| Tosnerová, T | 1 |
| Husovská, G | 1 |
| Raevskiĭ, KS | 1 |
| Aleksandrovskiĭ, IuA | 1 |
| Poiurovskiĭ, MV | 1 |
| Kharlamov, AN | 1 |
| Neznamov, GG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist[NCT00088699] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2004-07-26 | Completed | ||
| Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD[NCT02884908] | Phase 3 | 252 participants (Anticipated) | Interventional | 2016-09-30 | Active, not recruiting | ||
| Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms[NCT00202514] | Phase 2/Phase 3 | 40 participants | Interventional | 2004-09-30 | Completed | ||
| Prospective Assessment of Valproate on Ethanol Withdrawal[NCT03235531] | Phase 4 | 210 participants (Anticipated) | Interventional | 2017-07-11 | Recruiting | ||
| Monitoring of Seizures, EEG and Serum Antiepileptic Drug Concentrations in Patients With Uncontrolled Epilepsy[NCT00001149] | 900 participants | Observational | 1975-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 1.17 |
| Placebo - Healthy Volunteers | 1.48 |
| Ketamine - MDD Patients | 33.83 |
| Placebo - MDD Patients | 31.82 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 2.45 |
| Placebo - Healthy Volunteers | 0.67 |
| Ketamine - MDD Patients | 23.73 |
| Placebo - MDD Patients | 30.68 |
1 review available for valproic acid and Anxiety
| Article | Year |
|---|---|
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations.
Topics: Antipsychotic Agents; Anxiety; Aripiprazole; Bipolar Disorder; Canada; Humans; Olanzapine; Valproic | 2021 |
7 trials available for valproic acid and Anxiety
| Article | Year |
|---|---|
Effect of valproate and pregabalin on human anxiety-like behaviour in a randomised controlled trial.
Topics: Adult; Anti-Anxiety Agents; Anxiety; Bayes Theorem; Decision Making; Double-Blind Method; Female; He | 2018 |
A single infusion of ketamine improves depression scores in patients with anxious bipolar depression.
Topics: Adult; Affect; Anxiety; Anxiety Disorders; Bipolar Disorder; Cross-Over Studies; Depression; Double- | 2015 |
Effect of pregabalin augmentation in treatment of patients with combat-related chronic posttraumatic stress disorder: a randomized controlled trial.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Anxiety; Combat Disorders; Depression; Double-Blind M | 2014 |
Divalproex in the treatment of bipolar depression: a placebo-controlled study.
Topics: Adult; Ambulatory Care; Anticonvulsants; Antimanic Agents; Anxiety; Bipolar Disorder; Double-Blind M | 2005 |
The efficacy of divalproex sodium in the treatment of agitation associated with major depression.
Topics: Adult; Aged; Antimanic Agents; Anxiety; Depression; Depressive Disorder, Major; Female; Humans; Male | 2005 |
Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Anticonvulsants; Anxiety; Depression; Double-Blind Method; Etha | 2001 |
Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Anticonvulsants; Anxiety; Depression; Double-Blind Method; Etha | 2001 |
Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Anticonvulsants; Anxiety; Depression; Double-Blind Method; Etha | 2001 |
Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Anticonvulsants; Anxiety; Depression; Double-Blind Method; Etha | 2001 |
Does sodium valproate increase clinical effects of diazepam? Double blind study.
Topics: Anti-Anxiety Agents; Anxiety; Diazepam; Double-Blind Method; Drug Interactions; Humans; Valproic Aci | 1989 |
68 other studies available for valproic acid and Anxiety
| Article | Year |
|---|---|
2-Phenyl-3H-imidazo[4,5-b]pyridine-3-acetamides as non-benzodiazepine anticonvulsants and anxiolytics.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Anxiety; Benzodiazepines; Binding, Competitive; Cereb | 1991 |
Cilostazol attenuated prenatal valproic acid-induced behavioural and biochemical deficits in a rat model of autism spectrum disorder.
Topics: Animals; Anticonvulsants; Anxiety; Autism Spectrum Disorder; Behavior, Animal; Biomarkers; Brain; Ci | 2021 |
Valproic acid suppresses cuprizone-induced hippocampal demyelination and anxiety-like behavior by promoting cholesterol biosynthesis.
Topics: Animals; Anxiety; Cholesterol; Cuprizone; Demyelinating Diseases; Hippocampus; Male; Mice; Mice, Inb | 2021 |
Duloxetine ameliorates valproic acid-induced hyperactivity, anxiety-like behavior, and social interaction deficits in zebrafish.
Topics: Animals; Anxiety; Autism Spectrum Disorder; Behavior, Animal; Disease Models, Animal; Duloxetine Hyd | 2022 |
Anticonvulsant effects of Cymbopogon giganteus extracts with possible effects on fully kindled seizures and anxiety in experimental rodent model of mesio-temporal epilepsy induced by pilocarpine.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Anxiety; Cymbopogon; Disease Models, Animal; Dose-Res | 2022 |
Protective effects of L-carnitine against valproic acid-induced memory impairment and anxiety-like behavior in adult rat.
Topics: Animals; Anxiety; Carnitine; Male; Maze Learning; Memory Disorders; Rats; Rats, Wistar; Valproic Aci | 2022 |
Valproic Acid-Induced Anxiety and Depression Behaviors are Ameliorated in p39 Cdk5 Activator-Deficient Mice.
Topics: Animals; Anticonvulsants; Antimanic Agents; Anxiety; Cytoskeletal Proteins; Depression; Lipid-Linked | 2022 |
Inhalation of Cananga odorata essential oil relieves anxiety behaviors in autism-like rats via regulation of serotonin and dopamine metabolism.
Topics: Animals; Anxiety; Autistic Disorder; Cananga; Disease Models, Animal; Dopamine; Female; Oils, Volati | 2023 |
Ameliorating age-dependent effects of resveratrol on VPA-induced social impairments and anxiety-like behaviors in a rat model of neurodevelopmental disorder.
Topics: Animals; Anxiety; Autism Spectrum Disorder; Behavior, Animal; Disease Models, Animal; Female; Humans | 2023 |
Phosphodiesterase inhibitor, ibudilast alleviates core behavioral and biochemical deficits in the prenatal valproic acid exposure model of autism spectrum disorder.
Topics: Animals; Anxiety; Autism Spectrum Disorder; Disease Models, Animal; Female; Inflammation Mediators; | 2023 |
Increased Expression of Kv10.2 in the Hippocampus Attenuates Valproic Acid-Induced Autism-Like Behaviors in Rats.
Topics: Animals; Anxiety; Autistic Disorder; Behavior, Animal; Biological Therapy; Ether-A-Go-Go Potassium C | 2019 |
Contribution of neuronal calcium sensor 1 (Ncs-1) to anxiolytic-like and social behavior mediated by valproate and Gsk3 inhibition.
Topics: Animals; Anxiety; Cell Line; Disease Models, Animal; Down-Regulation; Frontal Lobe; Glycogen Synthas | 2020 |
A heritable profile of six miRNAs in autistic patients and mouse models.
Topics: Adolescent; Adult; Animals; Anxiety; Autism Spectrum Disorder; Autistic Disorder; Child; Child, Pres | 2020 |
Prenatal pregabalin is associated with sex-dependent alterations in some behavioral parameters in valproic acid-induced autism in rat offspring.
Topics: Animals; Anxiety; Autistic Disorder; Behavior, Animal; Choice Behavior; Disease Models, Animal; Fema | 2020 |
Targeting PPARα in the rat valproic acid model of autism: focus on social motivational impairment and sex-related differences.
Topics: Animals; Anxiety; Autistic Disorder; Behavior, Animal; Biomarkers; Disease Models, Animal; Female; F | 2020 |
Micromolar Valproic Acid Doses Preserve Survival and Induce Molecular Alterations in Neurodevelopmental Genes in Two Strains of Zebrafish Larvae.
Topics: Animals; Anticonvulsants; Anxiety; Autism Spectrum Disorder; Disease Models, Animal; Female; Larva; | 2020 |
Correlation of distinct behaviors to the modified expression of cerebral Shank1,3 and BDNF in two autistic animal models.
Topics: Animals; Anxiety; Autistic Disorder; Blotting, Western; Brain-Derived Neurotrophic Factor; Cerebrum; | 2021 |
Increasing Endocannabinoid Tone Alters Anxiety-Like and Stress Coping Behaviour in Female Rats Prenatally Exposed to Valproic Acid.
Topics: Animals; Anxiety; Anxiety Disorders; Autistic Disorder; Behavior, Animal; Disease Models, Animal; En | 2021 |
Do valproate preparations improve agitation in dementia? A Cochrane Review summary with commentary.
Topics: Anxiety; Dementia; Humans; Valproic Acid | 2021 |
Effect of early postnatal exposure to valproate on neurobehavioral development and regional BDNF expression in two strains of mice.
Topics: Animals; Animals, Newborn; Anticonvulsants; Anxiety; Behavior, Animal; Brain-Derived Neurotrophic Fa | 2017 |
Rescue of altered HDAC activity recovers behavioural abnormalities in a mouse model of Angelman syndrome.
Topics: Angelman Syndrome; Animals; Anxiety; Brain; Cell Line, Transformed; Cognition Disorders; Disease Mod | 2017 |
Impaired repair of DNA damage is associated with autistic-like traits in rats prenatally exposed to valproic acid.
Topics: Animals; Anxiety; Autistic Disorder; Disease Models, Animal; DNA Damage; DNA Repair; Dose-Response R | 2018 |
Serotonin depletion causes valproate-responsive manic-like condition and increased hippocampal neuroplasticity that are reversed by stress.
Topics: Animals; Anticonvulsants; Anxiety; Bipolar Disorder; Brain; Gene Expression Profiling; Hippocampus; | 2018 |
Nociceptin/orphanin FQ receptor agonists increase aggressiveness in the mouse resident-intruder test.
Topics: Aggression; Agonistic Behavior; Animals; Anxiety; Bipolar Disorder; Carbamazepine; Cycloheptanes; De | 2019 |
The histamine H3R antagonist DL77 attenuates autistic behaviors in a prenatal valproic acid-induced mouse model of autism.
Topics: Animals; Anxiety; Autistic Disorder; Behavior, Animal; Brain; Choice Behavior; Cytokines; Disease Mo | 2018 |
Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add-on therapy compared to levetiracetam and valproic acid.
Topics: Adult; Anticonvulsants; Anxiety; Drug Therapy, Combination; Epilepsy; Female; Humans; Irritable Mood | 2019 |
Benefits of Fenofibrate in prenatal valproic acid-induced autism spectrum disorder related phenotype in rats.
Topics: Animals; Anticonvulsants; Anxiety; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Br | 2019 |
Consequences of prenatal exposure to valproic acid in the socially monogamous prairie voles.
Topics: Aggression; Animals; Anxiety; Arvicolinae; Behavior, Animal; Female; Gene Expression Regulation, Dev | 2019 |
Beneficial effects of pioglitazone, a selective peroxisome proliferator-activated receptor-γ agonist in prenatal valproic acid-induced behavioral and biochemical autistic like features in Wistar rats.
Topics: Animals; Anticonvulsants; Anxiety; Autism Spectrum Disorder; Brain Chemistry; Cytokines; Exploratory | 2019 |
Comparative gene expression analysis of the amygdala in autistic rat models produced by pre- and post-natal exposures to valproic acid.
Topics: Amygdala; Animals; Animals, Newborn; Anxiety; Autistic Disorder; Behavior, Animal; Disease Models, A | 2013 |
Histone acetylation and expression of mono-aminergic transmitters synthetases involved in CUS-induced depressive rats.
Topics: Acetylation; Animals; Anxiety; Depression; Disease Models, Animal; Epigenesis, Genetic; Gene Express | 2014 |
Valproic acid effects in the hippocampus and prefrontal cortex in an animal model of post-traumatic stress disorder.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Cats; Disease Models, Animal; Extinction, Psychological; Fear | 2014 |
Administration of histone deacetylase inhibitor during neonatal period changes emotionality of adult male 129Sv mice.
Topics: Animals; Animals, Newborn; Anxiety; Conditioning, Psychological; Epigenesis, Genetic; Fear; Histone | 2014 |
Ameliorating effect of piperine on behavioral abnormalities and oxidative markers in sodium valproate induced autism in BALB/C mice.
Topics: Alkaloids; Animals; Anxiety; Autistic Disorder; Benzodioxoles; Biomarkers; Brain; Cognition; Disease | 2014 |
The effects of valproate and olanzapine on the abnormal behavior of diacylglycerol kinase β knockout mice.
Topics: Animals; Anxiety; Benzodiazepines; Cognition Disorders; Diacylglycerol Kinase; Disease Models, Anima | 2015 |
Astaxanthin improves behavioral disorder and oxidative stress in prenatal valproic acid-induced mice model of autism.
Topics: Animals; Anxiety; Autistic Disorder; Brain; Catalase; Disease Models, Animal; Female; Glutathione; L | 2015 |
Evaluating an etiologically relevant platform for therapy development for temporal lobe epilepsy: effects of carbamazepine and valproic acid on acute seizures and chronic behavioral comorbidities in the Theiler's murine encephalomyelitis virus mouse model
Topics: Animals; Anticonvulsants; Anxiety; Behavior, Animal; Carbamazepine; Cardiovirus Infections; Comorbid | 2015 |
Analytical strategies for the marble burying test: avoiding impossible predictions and invalid p-values.
Topics: Analysis of Variance; Animals; Anxiety; Autistic Disorder; Behavior, Animal; Calcium Carbonate; Dise | 2015 |
Epileptogenesis and epileptic maturation in phosphorylation site-specific SNAP-25 mutant mice.
Topics: Animals; Anticonvulsants; Anxiety; Blotting, Western; Brain; Disease Progression; Electrocorticograp | 2015 |
Postnatal Stress Induced by Injection with Valproate Leads to Developing Emotional Disorders Along with Molecular and Cellular Changes in the Hippocampus and Amygdala.
Topics: Amygdala; Animals; Anxiety; Astrocytes; Cell Count; Cell Differentiation; Cell Proliferation; Cell S | 2016 |
Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study.
Topics: Adult; Aged; Anticonvulsants; Anxiety; Carbamazepine; Depression; Drug-Related Side Effects and Adve | 2016 |
The effect of ketogenic diet in an animal model of autism induced by prenatal exposure to valproic acid.
Topics: Animals; Anticonvulsants; Anxiety; Autism Spectrum Disorder; Behavior, Animal; Diet, Ketogenic; Dise | 2017 |
Neonatal Maternal Separation Impairs Prefrontal Cortical Myelination and Cognitive Functions in Rats Through Activation of Wnt Signaling.
Topics: Animals; Animals, Newborn; Anxiety; Cognition Disorders; Demyelinating Diseases; Enzyme Inhibitors; | 2017 |
Increased anxiety-like behaviour and altered GABAergic system in the amygdala and cerebellum of VPA rats - An animal model of autism.
Topics: Amygdala; Animals; Anxiety; Autism Spectrum Disorder; Cerebellum; Disease Models, Animal; Female; GA | 2016 |
Human adipose-derived stem cells ameliorate repetitive behavior, social deficit and anxiety in a VPA-induced autism mouse model.
Topics: Adipose Tissue; Animals; Animals, Newborn; Anxiety; Autistic Disorder; Cumulative Trauma Disorders; | 2017 |
The supra-additive hyperactivity caused by an amphetamine-chlordiazepoxide mixture exhibits an inverted-U dose response: negative implications for the use of a model in screening for mood stabilizers.
Topics: Affect; Amphetamine; Animals; Antimanic Agents; Anxiety; Bipolar Disorder; Chlordiazepoxide; Disease | 2009 |
Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amygdala; Amyloid beta-Peptides; Amyloid beta-Protein Pr | 2010 |
Anti-depressant and anxiolytic like behaviors in PKCI/HINT1 knockout mice associated with elevated plasma corticosterone level.
Topics: Analysis of Variance; Animals; Anxiety; Avoidance Learning; Behavior, Animal; Corticosterone; Cues; | 2009 |
All is not lost: utilizing continuous remote ILR monitoring to diagnose syncope.
Topics: Anxiety; Arrhythmias, Cardiac; Electrocardiography, Ambulatory; Epilepsy, Absence; Humans; Male; Mid | 2010 |
Behavior in the open field predicts the number of KCl-induced cortical spreading depressions in rats.
Topics: Animals; Antimanic Agents; Anxiety; Behavior, Animal; Cortical Spreading Depression; Electrodes, Imp | 2013 |
Critical period for acoustic preference in mice.
Topics: Acoustic Stimulation; Animals; Anxiety; Auditory Cortex; Behavior, Animal; Female; GPI-Linked Protei | 2012 |
Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study.
Topics: Adult; Aged; Anticonvulsants; Anxiety; Benzodiazepines; Brain Neoplasms; Carbamazepine; Clobazam; Dr | 2012 |
Experimental anxiety and antiepileptics: the effects of valproate and vigabatrin in the mirrored chamber test.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Anxiety; Conflict, Psychological; Disease Models, Ani | 2003 |
Treatment of agitation using Depakote: a patient with dementia.
Topics: Affect; Aggression; Alzheimer Disease; Anxiety; Cooperative Behavior; Dose-Response Relationship, Dr | 2003 |
A psychotic episode associated with the Atkins diet in a patient with bipolar disorder.
Topics: Antimanic Agents; Anxiety; Bipolar Disorder; Confusion; Diet Fads; Humans; Ketosis; Male; Middle Age | 2005 |
Environmental enrichment reverses behavioral alterations in rats prenatally exposed to valproic acid: issues for a therapeutic approach in autism.
Topics: Animals; Anticonvulsants; Anxiety; Autistic Disorder; Behavior, Animal; Environment; Exploratory Beh | 2006 |
Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia.
Topics: Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Anxiety; Blood Glucose; Brief Psychi | 2006 |
Picrotoxin blocks the anxiolytic- and panicolytic-like effects of sodium valproate in the rat elevated T-maze.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Avoidance Learning; Escape Reaction; GABA Antagonists; Male; | 2006 |
Psychic disturbances associated with sodium valproate plus levetiracetam.
Topics: Anticonvulsants; Anxiety; Drug Therapy, Combination; Epilepsies, Partial; Female; Humans; Levetirace | 2007 |
Prenatal exposure to valproic acid disturbs the enkephalinergic system functioning, basal hedonic tone, and emotional responses in an animal model of autism.
Topics: Animals; Anticonvulsants; Anxiety; Autistic Disorder; Basal Ganglia; Conditioning, Classical; Diseas | 2007 |
The use of sodium valproate in the treatment of alcoholism.
Topics: Administration, Oral; Adult; Aged; Alcoholism; Anticonvulsants; Anxiety; Follow-Up Studies; Humans; | 1995 |
Effects of valproate and lorazepam on experimental anxiety: tolerance, withdrawal, and role of clonidine.
Topics: Adrenergic alpha-Agonists; Animals; Anti-Anxiety Agents; Anxiety; Avoidance Learning; Clonidine; Dru | 1995 |
Drugs for psychiatric disorders.
Topics: Aged; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety; Benzodi | 1997 |
Anxiolytic effects of valproate and diazepam in mice are differentially sensitive to picrotoxin antagonism.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Decision Making; Diazepam; Exploratory Behavior; GABA Antagon | 2001 |
Treatment of febrile seizures: the influence of treatment efficacy and side-effect profile on value to parents.
Topics: Adult; Anticonvulsants; Anxiety; Attitude; Child, Preschool; Diazepam; Educational Status; Female; H | 2001 |
The anxiogenic-like effects of pentylenetetrazole in mice treated chronically with carbamazepine or valproate.
Topics: Animals; Anxiety; Behavior, Animal; Carbamazepine; Female; Lorazepam; Mice; Pentylenetetrazole; Valp | 1992 |
Depression, anxiety, and temporal lobe epilepsy. Laterality of focus and symptoms.
Topics: Adult; Analysis of Variance; Anxiety; Carbamazepine; Depression; Epilepsy, Temporal Lobe; Female; Fu | 1990 |
[Anxiolytic action of sodium valproate (possible role of gamma-aminobutyric acid in affective disorders)].
Topics: Adult; Animals; Anti-Anxiety Agents; Anxiety; Brain; Cats; Female; gamma-Aminobutyric Acid; Humans; | 1985 |